The impact of selective dopamine D2, D3 and D4 ligands on the rat gambling task

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Di Ciano, Patricia ^a   Pushparaj, Abhiram ^a   Kim, Aaron ^a   Hatch, Jessica ^c   Masood, Talal ^a   Ramzi, Abby ^a   Khaled, Maram A T M ^a,d   Boileau, Isabelle ^b   Winstanley, Catherine A ^e   Le Foll, Bernard ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ALEXANDRIA UNIVERSITY   (Egypt)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LIGAND;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DECISION MAKING; LATENT PERIOD; MALE; NONHUMAN; PATHOLOGICAL GAMBLING; PUNISHMENT; RAT; REACTION TIME; REWARD; RISK ASSESSMENT; RISK FACTOR; TASK PERFORMANCE; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DRUG EFFECTS; GAMBLING; GAME; INSTRUMENTAL CONDITIONING; LONG EVANS RAT; PHYSIOLOGY;

ANIMALS; CONDITIONING, OPERANT; DECISION MAKING; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; DOPAMINE D2 RECEPTOR ANTAGONISTS; GAMBLING; GAMES, EXPERIMENTAL; LIGANDS; MALE; PUNISHMENT; RATS; RATS, LONG-EVANS; REACTION TIME; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, DOPAMINE D4; REWARD;

EID: 84943284263     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136267     Document Type: Article

References (45)

1. Association AP. DSM-5. Association AP, editor. Washington, D.C.: American Psychiatric Publishing; 2013.
2. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev. 1998; 28(3):309-69. PMID: 9858756
3. DiChiara G. Drug addiction as dopamine-dependent associative learning disorder. Eur J Pharmacol. 1999; 375(1-3):13-30. PMID: 10443561
4. Reuter J, Raedler T, Rose M, Hand I, Glascher J, Buchel C. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci. 2005; 8(2):147-8. Epub 2005/01/12. doi: 10.1038/nn1378 PMID: 15643429.
5. Zack M, Poulos CX. A D2 antagonist enhances the rewarding and priming effects of a gambling episode in pathological gamblers. Neuropsychopharmacology. 2007; 32(8):1678-86. PMID: 17203013
6. Linnet J, Moller A, Peterson E, Gjedde A, Doudet D. Inverse association between dopaminergic neurotransmission and Iowa Gambling Task performance in pathological gamblers and healthy controls. Scandinavian journal of psychology. 2011; 52(1):28-34. Epub 2010/08/14. doi: 10.1111/j.1467-9450.2010.00837.x PMID: 20704689.
7. Seedat S, Kesler S, Niehaus DJ, Stein DJ. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depression and anxiety. 2000; 11(4):185-6. Epub 2000/08/17. doi: 10.1002/1520-6394(2000)11:4<185::AID-DA8>3.0.CO;2-H PMID: 10945141.
8. Baik JH, Picetti R, Saiardi A, Thiriet G, Dierich A, Depaulis A, et al. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature. 1995; 377(6548):424-8. PMID: 7566118
9. Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, et al. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther. 2000; 294(3):1154-65. PMID: 10945872
10. Le Foll B, Gallo A, Le Strat Y, Lu L, Gorwood P. Genetics of dopamine receptors and drug addiction: a comprehensive review. Behav Pharmacol. 2009; 20(1):1-17. Epub 2009/01/31. doi: 10.1097/FBP.0b013e3283242f05 PMID: 19179847.
11. Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord DrugTargets. 2006; 5(1):25-43. Epub 2006/04/15. PMID: 16613552.
12. Nakajima S, Gerretsen P, Takeuchi H, Caravaggio F, Chow T, Le Foll B, et al. The potential role of dopamine D3 receptor neurotransmission in cognition. Eur Neuropsychopharmacol. 2013;in press. doi: 10.1016/j.euroneuro.2013.05.006 PMID: 23791072.
13. Le Foll B, Goldberg SR, Sokoloff P. The dopamine D3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology. 2005; 49(4):525-41. Epub 2005/06/21. doi: S0028-3908(05)00155-3 [pii] doi: 10.1016/j.neuropharm.2005.04.022 PMID: 15963538.
14. Khaled M, Pushparaj A, Di Ciano P, Diaz J, Le foll B. Dopamine D3 receptors in the basolateral amygdala and the lateral habenula modulate cue-induced reinstatement of nicotine-seeking. Neuropsychopharmacology. 2014;in press.
15. Heidbreder C. Novel pharmacotherapeutic targets for the management of drug addiction. Eur J Pharmacol. 2005; 526(1-3):101-12. PMID: 16253234
16. Bouthenet ML, Souil E, Martres MP, Sokoloff P, Giros B, Schwartz JC. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res. 1991; 564(2):203-19. PMID: 1839781
17. Diaz J, Pilon C, Le Foll B, Gros C, Triller A, Schwartz JC, et al. Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci. 2000; 20(23):8677-84. PMID: 11102473
18. Valerio A, Belloni M, Gorno ML, Tinti C, Memo M, Spano P. Dopamine D2, D3, and D4 receptor mRNA levels in rat brain and pituitary during aging. Neurobiology of aging. 1994; 15(6):713-9. Epub 1994/11/01. PMID: 7891826.
19. 4 receptor sequence, gene structure, and demonstration of expression in the cardiovascular system. The New Biologist. 1992; 2:137-46.
20. Meador-Woodruff JH, Grandy DK, Van Tol HHM, Damask SP, Little KY, Civelli O, et al. Dopamine receptor gene expression in the human medial temporal lobe. Neuropsychopharmacol. 1994; 10:239-48.
21. Meador-Woodruff JH, Haroutunian V, Powchik P, Davidson M, Davis KL, Watson SJ. Dopamine receptortranscript expression in striatum and prefrontal and occipital cortex. Arch Gen Psychiatry. 1997; 54:1089-95. PMID: 9400344
22. Mrzljak L, Bergson C, Pappy M, Huff R, Levenson R, Goldman-Rakic PS. Localization of dopamine D4 receptors in GABAergic neurons of the primate brain. Nature. 1996; 381(6579):245-8. Epub 1996/05/16. doi: 10.1038/381245a0 PMID: 8622768.
23. 4 receptors coupled to adenylate cyclase. Proc Natl Acad Sci USA. 1992; 89:12093-7. PMID: 1334557
24. Bechara A, Damasio AR, Damasio H, Anderson SW. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition. 1994; 50(1-3):7-15. Epub 1994/04/01. PMID: 8039375.
25. Zeeb FD, Robbins TW, Winstanley CA. Serotonergic and dopaminergic modulation of gambling behavior as assessed using a novel rat gambling task. Neuropsychopharmacology. 2009; 34(10):2329-43. Epub 2009/06/19. doi: 10.1038/npp.2009.62 PMID: 19536111.
26. Winstanley CA, Cocker PJ, Rogers RD. Dopamine modulates reward expectancy during performance of a slot machine task in rats: evidence for a 'near-miss' effect. Neuropsychopharmacology. 2011; 36(5):913-25. Epub 2011/01/07. doi: 10.1038/npp.2010.230 PMID: 21209612; PubMed Central PMCID: PMC3077261.
27. Cocker PJ, Le Foll B, Rogers RD, Winstanley CA. A Selective Role for Dopamine D Receptors in Modulating Reward Expectancy in a Rodent Slot Machine Task. Biol Psychiatry. 2013. Epub 2013/10/08. doi: 10.1016/j.biopsych.2013.08.026 PMID: 24094512.
28. Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, et al. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. The Journal Pharmacology and Experimental Therapeutics. 2000; 294(3):1154-65.
29. Kulagowski JJ, Broughton HB, Curtis NR, Mawer IM, Ridgill MP, Baker R, et al. 3-((4-(4-Chlorophenyl) piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor. J Med Chem. 1996; 39(10):1941-2. doi: 10.1021/jm9600712 PMID: 8642550.
30. Achat-Mendes C, Grundt P, Cao J, Platt DM, Newman AH, Spealman RD. Dopamine D3 and D2 receptor mechanisms in the abuse-related behavioral effects of cocaine: studies with preferential antagonists in squirrel monkeys. J Pharmacol Exp Ther. 2010; 334(2):556-65. Epub 2010/05/25. doi: 10.1124/jpet.110.167619 PMID: 20494958; PubMed Central PMCID: PMC2913766.
31. Yan Y, Pushparaj A, Le Strat Y, Gamaleddin I, Barnes C, Justinova Z, et al. Blockade of dopamine d4 receptors attenuates reinstatement of extinguished nicotine-seeking behavior in rats. Neuropsychopharmacology. 2012; 37(3):685-96. Epub 2011/10/28. doi: 10.1038/npp.2011.245 PMID: 22030716; PubMed Central PMCID: PMC3260983.
32. Cocker PJ, Dinelle K, Kornelson R, Sossi V, Winstanley CA. Irrational choice under uncertainty correlates with lower striatal D(2/3) receptor binding in rats. J Neurosci. 2012; 32(44):15450-7. Epub 2012/11/02. doi: 10.1523/JNEUROSCI.0626-12.2012 PMID: 23115182.
33. Heidbreder CA, Gardner EL, Xi ZX, Thanos PK, Mugnaini M, Hagan JJ, et al. The role of central dopamine D(3) receptors in drug addiction: a review of pharmacological evidence. Brain Res Brain Res Rev. 2005; 49(1):77-105. PMID: 15960988
34. Payer D, Balasubramaniam G, Boileau I. What is the role of the D receptor in addiction? A mini review of PET studies with [C]-(+)-PHNO. Prog Neuropsychopharmacol Biol Psychiatry. 2013. Epub 2013/09/04. doi: 10.1016/j.pnpbp.2013.08.012 PMID: 23999545.
35. Lobo DS, Aleksandrova L, Knight J, Casey DM, El-Guebaly N, Nobrega JN, et al. Addiction-related genes in gambling disorders: new insights from parallel human and pre-clinical models. Mol Psychiatry. 2014. doi: 10.1038/mp.2014.113 PMID: 25266122.
36. Paine TA, Asinof SK, Diehl GW, Frackman A, Leffler J. Medial prefrontal cortex lesions impair decisionmaking on a rodent gambling task: reversal by D1 receptor antagonist administration. Behav Brain Res. 2013; 243:247-54. doi: 10.1016/j.bbr.2013.01.018 PMID: 23354057; PubMed Central PMCID: PMC3633084.
37. Baarendse PJ, Winstanley CA, Vanderschuren LJ. Simultaneous blockade of dopamine and noradrenaline reuptake promotes disadvantageous decision making in a rat gambling task. Psychopharmacology (Berl). 2013; 225(3):719-31. doi: 10.1007/s00213-012-2857-z PMID: 22968659; PubMed Central PMCID: PMC3531574.
38. Nakajima S, Gerretsen P, Takeuchi H, Caravaggio F, Chow T, Le Foll B, et al. The potential role of dopamine D3 receptor neurotransmission in cognition. Eur Neuropsychopharmacol. 2013; 23(8):799-813. Epub 2013/06/25. doi: 10.1016/j.euroneuro.2013.05.006 PMID: 23791072; PubMed Central PMCID: PMC3748034.
39. Watson DJ, Loiseau F, Ingallinesi M, Millan MJ, Marsden CA, Fone KC. Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex. Neuropsychopharmacology. 2012; 37(3):770-86. Epub 2011/10/28. doi: 10.1038/npp.2011.254 PMID: 22030711; PubMed Central PMCID: PMC3261029.
40. Millan MJ, Loiseau F, Dekeyne A, Gobert A, Flik G, Cremers TI, et al. S33138(N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects. J Pharmacol Exp Ther. 2008; 324(3):1212-26. Epub 2007/12/22. doi: 10.1124/jpet.107.134536 PMID: 18096759.
41. Harrison AA, Everitt BJ, Robbins TW. Central 5-HT depletion enhances impulsive responding without affecting the accuracy of attentional performance: interactions with dopaminergic mechanisms. Psychopharmacology (Berl). 1997; 133(4):329-42. Epub 1998/01/24. PMID: 9372531.
42. Browman KE, Curzon P, Pan JB, Molesky AL, Komater VA, Decker MW, et al. A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats. Pharmacol Biochem Behav. 2005; 82(1):148-55. Epub 2005/09/13. doi: 10.1016/j.pbb.2005.08.002 PMID: 16154186.
43. Bernaerts P, Tirelli E. Facilitatory effect of the dopamine D4 receptor agonist PD168,077 on memory consolidation of an inhibitory avoidance learned response in C57BL/6J mice. Behav Brain Res. 2003; 142(1-2):41-52. Epub 2003/06/12. PMID: 12798264.
44. Woolley ML, Waters KA, Reavill C, Bull S, Lacroix LP, Martyn AJ, et al. Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in rat. Behav Pharmacol. 2008; 19(8):765-76. Epub 2008/11/21. doi: 10.1097/FBP.0b013e32831c3b06 PMID: 19020411.
45. Young JW, Powell SB, Scott CN, Zhou X, Geyer MA. The effect of reduced dopamine D4 receptor expression in the 5-choice continuous performance task: Separating response inhibition from premature responding. Behav Brain Res. 2011; 222(1):183-92. Epub 2011/04/05. doi: 10.1016/j.bbr.2011.03.054 PMID: 21458500; PubMed Central PMCID: PMC3531561.